Carter Gould
Stock Analyst at Barclays
(3.24)
# 1,046
Out of 4,711 analysts
199
Total ratings
45.3%
Success rate
2.01%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Equal-Weight | $84 → $95 | $92.57 | +2.63% | 14 | Nov 7, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,080 → $1,065 | $701.85 | +51.74% | 19 | Nov 1, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $18 → $20 | $17.18 | +16.41% | 6 | Nov 1, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $1,025 → $975 | $767.76 | +26.99% | 11 | Oct 31, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $180 | $146.47 | +22.89% | 24 | Oct 31, 2024 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $42 → $43 | $57.33 | -25.00% | 14 | Oct 7, 2024 | |
| MRK Merck & Co. | Maintains: Overweight | $142 → $140 | $98.05 | +42.78% | 10 | Oct 7, 2024 | |
| AMGN Amgen | Maintains: Equal-Weight | $300 → $315 | $263.38 | +19.60% | 16 | Oct 7, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $200 → $212 | $175.58 | +20.74% | 14 | Oct 7, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $160 | $135.42 | +18.15% | 11 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $84.22 | +18.74% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $0.87 | +245.90% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $32 | $26.36 | +21.40% | 14 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.11 | +170.27% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.49 | +157.88% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $48.87 | +94.39% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $19.30 | +3.63% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $75.54 | -3.36% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $1.20 | -16.67% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.86 | +545.16% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.84 | +78.57% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $68 → $15 | $0.16 | +9,275.00% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.88 | +155.65% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $207.23 | +83.37% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $68.84 | +19.12% | 5 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $183 → $188 | $397.27 | -52.68% | 1 | Jul 26, 2018 |
Gilead Sciences
Nov 7, 2024
Maintains: Equal-Weight
Price Target: $84 → $95
Current: $92.57
Upside: +2.63%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,080 → $1,065
Current: $701.85
Upside: +51.74%
Travere Therapeutics
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $17.18
Upside: +16.41%
Eli Lilly
Oct 31, 2024
Maintains: Overweight
Price Target: $1,025 → $975
Current: $767.76
Upside: +26.99%
Biogen
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $146.47
Upside: +22.89%
Bristol-Myers Squibb Company
Oct 7, 2024
Maintains: Underweight
Price Target: $42 → $43
Current: $57.33
Upside: -25.00%
Merck & Co.
Oct 7, 2024
Maintains: Overweight
Price Target: $142 → $140
Current: $98.05
Upside: +42.78%
Amgen
Oct 7, 2024
Maintains: Equal-Weight
Price Target: $300 → $315
Current: $263.38
Upside: +19.60%
AbbVie
Oct 7, 2024
Maintains: Overweight
Price Target: $200 → $212
Current: $175.58
Upside: +20.74%
Neurocrine Biosciences
Sep 9, 2024
Maintains: Overweight
Price Target: $180 → $160
Current: $135.42
Upside: +18.15%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $84.22
Upside: +18.74%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $0.87
Upside: +245.90%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $30 → $32
Current: $26.36
Upside: +21.40%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.11
Upside: +170.27%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $3.49
Upside: +157.88%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $48.87
Upside: +94.39%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $19.30
Upside: +3.63%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $75.54
Upside: -3.36%
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $1.20
Upside: -16.67%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.86
Upside: +545.16%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.84
Upside: +78.57%
Nov 11, 2022
Maintains: Overweight
Price Target: $68 → $15
Current: $0.16
Upside: +9,275.00%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.88
Upside: +155.65%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $207.23
Upside: +83.37%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $68.84
Upside: +19.12%
Jul 26, 2018
Maintains: Neutral
Price Target: $183 → $188
Current: $397.27
Upside: -52.68%